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Human Bocavirus
in Children
To the Editor: Respiratory tract
infection is a major cause of illness in
children. Despite the availability of
sensitive diagnostic methods, detect-
ing infectious agents is difficult in a
substantial proportion of respiratory
samples from children with respirato-
ry tract disease (1). This fact suggests
the existence of currently unknown
respiratory pathogens.
A new virus has been recently
identified in respiratory samples from
children with lower respiratory tract
disease in Sweden (2). Analysis of the
full-length genome sequence showed
that this virus is closely related to
bovine parvovirus and canine minute
virus and is a member of the genus
Bocavirus, subfamily Parvovirinae,
family  Parvoviridae. This virus has
been provisionally named human
Bocavirus (HBoV) (2). HBoV in res-
piratory samples from Australian chil-
dren was also recently reported (3).
Involvement of this new virus in res-
piratory tract diseases merits further
investigation. We have therefore ret-
rospectively tested for HBoV
nasopharyngeal samples collected
from children <5 years of age hospi-
talized with respiratory tract disease. 
Samples were collected from 262
children from November 1, 2003, to
January 31, 2004. The samples were
tested for respiratory viruses by using
direct immunofluorescence assays
with monoclonal antibodies to respi-
ratory syncytial virus; influenza virus
types A and B; parainfluenza virus
types 1, 2, and 3; and adenovirus.
Samples were also placed on MRC5
cell monolayers for virus isolation
and tested for human metapneu-
movirus by reverse transcription–
polymerase chain reaction (RT-PCR).
Nucleic acids were extracted from
samples, stored at –80°C, and tested
for HBoV DNA by PCR with primers
specific for the predicted NP1 gene as
previously described (2). The expect-
ed product size was 354 bp. In each
experiment, a negative control was
included, and positive samples were
confirmed by analyzing a second
sample. Amplification specificity was
verified by sequencing. 
Nine (3.4%) samples were posi-
tive. Comparison of PCR product
sequences of these 9 isolates
(GenBank accession nos. AM109958–
AM109966) showed minor differ-
ences that occurred at 1 to 4 nucleotide
positions, and a high level of sequence
identity (99%–100%) was observed
with the NP1 sequences of the previ-
ously identified ST1 and ST2 isolates
(2). This finding indicates that HBoV
is a highly conserved virus.
HBoV was the only virus identified
in 6 children and was associated with
respiratory syncytial virus in 3 other
children. An infection with other res-
piratory viruses was detected among
153 (60.5%) of the 253 HBoV-nega-
tive children. The viruses identified
were respiratory syncytial virus in 114
(43.5%) samples, human metapneu-
movirus in 27 (10.3%) samples,
influenza A virus in 14 (5.4%) sam-
ples, rhinovirus in 4 (1.5%) samples,
adenovirus in 2 (0.8%) samples, and
parainfluenza virus type 3 in 1 (0.4%)
sample. Respiratory syncytial virus
was associated with human metapneu-
movirus in 9 (3.4%) samples.
Clinical characteristics of the
HBoV-infected children are shown in
the Table. Children infected with only
HBoV had mild-to-moderate fevers.
Leukocyte counts and C-reactive pro-
tein levels were normal or moderately
elevated. Chest radiographs obtained
for 7 children showed abnormalities
such as hyperinflation and interstitial
infiltrates. Bronchiolitis was the
major diagnosis. Dyspnea, respiratory
distress, and cough were the most
common respiratory symptoms
observed. Four (44%) HBoV-infected
children were born preterm, which
suggests that these children have an
increased susceptibility to HBoV-
associated diseases. All children
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recovered and were discharged within
1 to 6 days.
The 3.4% incidence of HBoV
observed in our study is similar to that
(3.1%) reported by Allander et al. (2).
HBoV was the only infectious agent
identified in 6 children, which sug-
gests that it was the causative agent of
the disease. However, more studies
conducted in children with and with-
out respiratory disease as well as in
adults and elderly persons are needed
to better assess the pathogenic role of
HBoV. 
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Extended-spectrum
β-Lactamase–
producing
Enterobacteriaceae,
Central African
Republic
To the Editor: Since the early
1980s, extended-spectrum β-lacta-
mases (ESBLs) have been the largest
source of resistance to broad-spec-
trum oxyimino-cephalosporins among
Enterobacteriaceae (1). Molecular
analysis techniques suggest that many
ESBLs are derived from mutations in
TEM-1, TEM-2, and SHV-1 β-lacta-
mases and that these ESBLs can
hydrolyze the extended-spectrum
cephalosporins (particularly cef-
tazidime) and aztreonam (1).
Members of a new group of ESBLs
have been recently identified (1).
Among them, CTX-M–type ESBLs
are rapidly expanding and are derived
from chromosomal class A β-lacta-
mases of Kluyvera spp. (1,2). The
CTX-M enzymes are not related to
TEM or SHV enzymes, as they share
only 40% identity with these ESBLs
(2).These ESBLS are usually charac-
terized by a higher level of resistance
to cefotaxime than ceftazidime,
except for CTX-M-19 (2). Most
organisms that harbor ESBLs are also
resistant to other classes of antimicro-
bial drugs, such as aminoglycosides,
fluoroquinolones, chloramphenicol,
and tetracyclines (1,2).
Reports concerning the existence
of ESBL-producing Enterobac-
teriaceae in sub-Saharan Africa are
scarce. We therefore conducted a
study in the Central African Republic
to determine the frequency of ESBLs
in Enterobacteriaceae isolated at the
Institut Pasteur de Bangui and to char-
acterize their blaTEM,  blaSHV, and
blaCTX-M genes.
From January 2003 to March
2005, all Enterobacteriaceae isolated
from human specimens at the Institut
Pasteur de Bangui were screened for
ESBLs. Antimicrobial drug suscepti-
bility was determined by using the
disk diffusion method (Bio-Rad,
Marnes la Coquette, France) on
Mueller-Hinton agar (MHA) and
interpreted according to the recom-
mendations of the Comité de
l’Antibiogramme de la Société